Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Core Viewpoint - Xencor (XNCR) shares experienced a significant increase of 7.3% in the last trading session, closing at $9.25, driven by strong trading volume and investor optimism regarding its engineered antibodies for cancer and autoimmune diseases [1] Company Summary - Xencor is projected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of -1.4% [2] - Expected revenues for Xencor are $25.66 million, which represents a substantial increase of 139.6% compared to the same quarter last year [2] - The consensus EPS estimate for Xencor has remained unchanged over the past 30 days, indicating a lack of recent earnings estimate revisions [4] Industry Summary - Xencor is part of the Zacks Medical - Drugs industry, where another company, Aclaris Therapeutics (ACRS), saw a decline of 1.6% in its last trading session, closing at $1.81 [5] - Aclaris is expected to report an EPS estimate of -$0.13, which is a change of -18.2% from the previous year [6]